RT Journal Article
SR Electronic
T1 A <em>FLOT1</em> host regulatory allele is associated with a recently expanded <em>Mtb</em> clade in patients with tuberculosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.07.22270622
DO 10.1101/2022.02.07.22270622
A1 Luo, Yang
A1 Huang, Chuan-Chin
A1 Liu, Qingyun
A1 Howard, Nicole
A1 Li, Xinyi
A1 Zhu, Junhao
A1 Amariuta, Tiffany
A1 Asgari, Samira
A1 Ishigaki, Kazuyoshi
A1 Calderon, Roger
A1 Moody, D. Branch
A1 Lecca, Leonid
A1 Fortune, Sarah M.
A1 Murray, Megan B.
A1 Raychaudhuri, Soumya
YR 2022
UL http://medrxiv.org/content/early/2022/02/08/2022.02.07.22270622.abstract
AB The outcome of infectious diseases may depend on the interaction between human and pathogen genomic variations. We explore this relationship in tuberculosis (TB) by conducting a genome-to-genome (g2g) study of paired genomes from humans and the infectious agent Mycobacterium tuberculosis (Mtb) in 1,556 Peruvian TB patients. We identified a significant association between a human variant in the FLOT1 gene and a unique Mtb Lineage 2 (L2) subclade. The host allele affects FLOT1 expression in multiple tissue and cell types including lung, the primary site of TB disease. Phylogenetic analysis shows that the Mtb subclade has expanded rapidly in Peru since its emergence in the 1950s. Unbiased phenotypic profiling demonstrates that strains from the interacting Mtb subclade display different redox metabolism from other L2 strains. This study presents clear evidence that human and bacterial genetic variation interact together to produce different clinical outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Institutes of Health (NIH) TB Research Unit Network, Grant U19 AI111224 and NHGRI U01 HG009379.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Harvard School of Public Health and by the Research Ethics Committee of the National Institute of Health of Peru.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data for generating the figures presented in the manuscript are available at https://github.com/immunogenomics/TB-g2g. Human genotyping data are available through dbGAP, under accession number phs002025.v1.p1.